HOWL Q2 2023 Earnings — Werewolf Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HOWLWerewolf Therapeutics, Inc.

$35M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+94.8% YoY

Gross Profit

$8M100.0% margin

Operating Income

-$6M-75.1% margin

Net Income

-$5M-63.1% margin

EPS (Diluted)

$-0.14

QoQ Revenue Growth

+81.0%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$185M

Total Liabilities

$67M

Stockholders' Equity

$119M

Cash & Equivalents

$137M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$4M	+94.8%
Gross Profit	$8M	-$10M	+183.0%
Operating Income	-$6M	-$15M	+59.5%
Net Income	-$5M	-$15M	+65.1%